Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences brings together leading immunology specialists to develop therapies for autoimmune pathologies, providing employees with high compensation and scientific autonomy. The EV/EBITDA market trend for the company stands at 0.00. The business integrates ESG principles into its biotechnological research, strictly adhering to bioethics and waste disposal standards. Stability is guaranteed by a robust patent portfolio and a focus on selective inhibitors, which protects developments from replication.
KZR (Kezar Life Sciences Inc.): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Kezar Life Sciences|KZR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Kezar Life Sciences Inc.|KZR - Company Aggregate Debts|Debts to Book Capitalization Kezar Life Sciences Inc|KZR - Long-Term Debt|Company Current Liabilities Kezar Life Sciences|Quick Ratio kezarlifesciences.com
- net income and valuation multiples indicators:
KZR - Net Profit|Expected Profit Kezar Life Sciences|KZR - Company Value to Net Income|Projected Price to Earnings Kezar Life Sciences, Inc.|KZR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc.|KZR - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Kezar Life Sciences|KZR - Net earnings per share for the last four quarters|Quarterly EPS earnings growth kezarlifesciences.com|KZR - Earnings per share trend in current year|Earnings growth forecast for next year Kezar Life Sciences
- total revenue and sales volume data:
Fundamental company analysis:Kezar Life Sciences Inc. KZR
For Kezar Life Sciences (KZR), the EV/EBITDA ratio serves as a measure of the total business value relative to its operational efficiency, combining market capitalization and net debt. By analyzing the EV/EBITDA dynamics of this capital-intensive business, an investor can see the gap between immunotherapy development costs and the lack of profit, confirming the company's high dependence on external financing amid constant liquidity burn.
Competitor analysis
EV/EBITDA Multiple ARGX (argenx.com)|Total Company Value to Operating Income Before Depreciation Ratio biontech.de (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADMA Biologics Inc (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist Corp (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant, Inc.|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple grifols.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp (ADPT)|Celldex Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (auriniapharma.com)|BioCryst Pharmaceuticals Inc (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Therapeutics) - Enterprise Value to Operating Income Before Depreciation|PHVS: EV/EBITDA Multiple|ABCL (AbCellera Biologics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Intrexon PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group N.V. (PHAR)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|EV/EBITDA Multiple UPB (Upstream Pharma)|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Corp (GOSS) - Enterprise Value to EBITDA Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation SEPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|Savara Inc (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|Total Company Value to Operating Income Before Depreciation Ratio AnaptysBio Inc.|EV/EBITDA Multiple ATXS (Astria Therapeutics Inc)|enGene Holdings Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (aerovatetx.com)|Aclaris (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kyverna - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TLSA|Company Value to EBITDA Cabaletta Bio CABA|EV/EBITDA Multiple VTYX|Theratechnologies (THTX) - Enterprise Value to EBITDA Multiple|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|Eledon Pharmaceuticals (ELDN) - Company Value to EBITDA|Agenus, Inc - EV/EBITDA Multiple|Company Value to EBITDA climbbio.com|ZURA (Zura Bio Limited) - Enterprise Value to EBITDA Ratio|aTyr (ATYR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ADAG|IMA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Therapeutics (STTK)|Enterprise Value to EBITDA Ratio Equillium EQ|Connect Biopharma Holdings Limited - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|inflarx.de (IFRX) - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation X4 Pharmaceuticals XFOR|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization celularity.com|INMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BRNS|SABS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|GOVX - EV/EBITDA Multiple|Edesa Biotech Corp (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carismatx.com|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Business Value to Operating Income Before Depreciation|Aptevo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ReShape Lifesciences|Enterprise Value to EBITDA Ratio REVB|Indaptus Corp (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scinai.com (SCNI)|Enterprise Value to EBITDA Ratio CalciMedica CALI|EV/EBITDA Multiple AFMD (affimed.com)|Allakos Inc. (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGMS (igmbio.com) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC BioPharm|Third Harmonic Bio Inc. (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
